RESUMO
Objective: The purpose of the present study was to investigate the expression of the α2-integrin subunit and heat shock protein 47 (Hsp47) in two families with isolated gingival fibromatosis (GF) form and one family with GF associated with dental abnormalities and normal gingiva (NG). Study Design: Immunohistochemistry was performed with antibodies against α2-integrin and Hsp47 in specimens from two unrelated families with hereditary gingival fibromatosis (Families 1 and 2) and from one family with a gingival fibromatosis-associated dental abnormality (Family 3); NG samples were used for comparison. The results were analysed statistically. Results: Immunoreactivity for α2-integrin and Hsp47 was observed in the nucleus of epithelial cells of both the basal and suprabasal layer and a more discreet signal was noted in connective tissue in all study samples. Hsp47 showed higher immunoreactivity in Family 2 compared with the other families (p≤0.05). Despite the markup α2-integrin was higher in Family 3 there was no statistically significant difference between the families studied (p≥0.05). Conclusions: Our results confirmed the heterogeneity of GF, such that similar patterns of expression of the condition may show differences in the expression of proteins such as Hsp47. Although no difference in α2-integrin expression was observed between GF and NG groups, future studies are necessary to determine the exact role of this protein in the various forms of GF and whether it contributes to GF pathogenesis (AU)
No disponible
Assuntos
Humanos , Integrina alfa2/análise , Proteínas de Choque Térmico HSP47/análise , Fibromatose Gengival/patologia , Anormalidades Dentárias/epidemiologia , Predisposição Genética para Doença/genéticaRESUMO
Los tres agentes inhibidores de la glucoproteína IIb/IIIa actualmente en uso clínico, abciximab, eptifibatida y tirofibán, comparten como diana terapéutica el bloqueo de la vía final común de la agregación plaquetaria, pero difieren significativamente en su estructura química, en la forma de bloquear la integrina α2bβ3 plaquetaria y en la especificidad por el receptor. Como consecuencia de ello, el patrón de inhibición de cada uno de estos fármacos en la funcionalidad plaquetaria varía y la equivalencia de beneficio clínico para una misma indicación es cuestionable. Hoy por hoy, no se dispone de ensayos clínicos de equivalencia que nos permitan aceptar o excluir un efecto de clase para los inhibidores de la glucoproteína IIb/IIIa en una determinada indicación clínica. Los resultados de los metaanálisis realizados en las diversas indicaciones clínicas tampoco han sido concluyentes, ya que no siempre muestran beneficios clínicos similares en magnitud y dirección para cada uno de los inhibidores de la glucoproteína IIb/IIIa. Por lo tanto, no podemos recomendar el intercambio o sustitución de un inhibidor por otro más allá de la indicación particular para la que se lo haya estudiado y aprobado (AU)
The three glycoprotein-IIb/IIIa inhibitors currently in clinical use, abciximab, eptifibatide and tirofiban, all share the same therapeutic target, namely blockade of the final common pathway of platelet aggregation. However, they differ significantly in chemical structure, in the way in which they block platelet integrin α2bβ3, and in specificity for the receptor. Consequently, each drug inhibits platelet function in a different way and it is unclear whether they offer equivalent clinical benefits for the same indication. To date, there have been no clinical trials on the equivalence of these drugs that would enable us to conclude that glycoprotein-IIb/IIIa inhibitors either do or do not exhibit a class effect for any particular clinical indication. Moreover, the findings of meta-analyses carried out for various indications have been inconclusive because the magnitude and direction of the clinical benefits associated with different glycoprotein-IIb/IIIa inhibitors have often diverged. Therefore, the exchange or substitution of one glycoprotein-IIb/IIIa inhibitor for another cannot be recommended beyond the specific indication for which the drug has been investigated and approved (AU)
Assuntos
Humanos , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/antagonistas & inibidores , Síndrome Coronariana Aguda/tratamento farmacológico , Inibidores da Agregação Plaquetária/uso terapêutico , Integrina alfa2 , Resultado do TratamentoRESUMO
No disponible
